Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
|Articles|November 18, 2014
Correct: Exogenous Ochronosis
Learn more about Exogenous Ochronosis
Advertisement
CORRECT!
This image appears with permission from VisualDx. © Logical Images, Inc.
A 65-year-old man complains of this hyperpigmented rash on his face, which has been there for more than 2 years. He has been using bleaching cream, but it has not helped.
Learn more about Exogenous Ochronosis:
Advertisement
Related to this article
The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic keratoses on the extremities, neck, and trunk.
The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.
A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restoration of epidermal barrier integrity.
The approval of the oral BTKi rests on a phase 3 result of 29.3% complete response from hives vs 14.0% with placebo at week 12.
This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photography, and radiofrequency microneedling for rosacea.
Celltrion’s US launch of omalizumab-igec adds an interchangeable biosimilar option for eligible patients with chronic spontaneous urticaria.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Remibrutinib for Symptomatic Dermographism
2
Abrocitinib Reduces Pathogenic Skin-Resident Memory T Cells in Atopic Dermatitis
3
Previewing the 2026 Fall Clinical Dermatology Conference
4
Personalized Prescription Skin Care: Curology’s Whitney Tolpinrud, MD, on the Evolution of Virtual Dermatology
5